You are here

  • Home
  • Archive
  • Volume 90, Issue 6
  • Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003–2006

Article Text

Article menu
Download PDFPDF
Epidemiology
Short report
Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003–2006
  1. Camille E Introcaso1,
  2. Eileen F Dunne1,
  3. Susan Hariri1,
  4. Gitika Panicker2,
  5. Elizabeth R Unger2,
  6. Lauri E Markowitz1
  1. 1Division of Sexually Transmitted Disease Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  2. 2Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  1. Correspondence to Dr Eileen F Dunne, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention, CDC, 1600 Clifton Rd, MS E-02, Atlanta, GA 30030, USA; dde9{at}cdc.gov

Abstract

Background A vaccine is available to prevent human papillomavirus (HPV) 6, 11, 16 and 18; in the prevaccine era, seropositivity to vaccine types is a measure of natural exposure.

Methods We describe HPV seropositivity in the USA among 14–59-year-olds using the 2003–2006 National Health and Nutrition Examination Surveys.

Results Seropositivity to HPV 6, 11, 16 and 18 was 17.5%, 6.8%, 15.1% and 5.9%, respectively, among women, and 7.0%, 2.4%, 5.2% and 1.5%, respectively, among men. Overall in both sexes, seropositivity was 22.5% for any vaccine type (31.8% in women and 12.9% in men), but substantially lower for three or more types (1.7% overall, 2.8% in women and 0.6% in men).

Conclusions Almost a quarter of the participants were seropositive to any HPV vaccine type but few were seropositive to at least three vaccine HPV types in the prevaccine era. Further study is needed to assess if seropositivity would be useful as a biological marker of vaccination.

  • HPV
  • Epidemiology (General)
  • Surveillance
  • Virology Clinical

https://doi.org/10.1136/sextrans-2013-051490

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text